Carlos Iribarren to Survival Analysis
This is a "connection" page, showing publications Carlos Iribarren has written about Survival Analysis.
Connection Strength
0.207
-
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017 05; 139(5):1678-1680.
Score: 0.136
-
The metabolic syndrome is no better than its components. Minerva Cardioangiol. 2007 Aug; 55(4):487-9.
Score: 0.071